Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. An intermittent strategy with fluorouracil, leucovorin and irinotecan (FOLFIRI) plus panitumumab (PAN) following induction was feasible, showed reduced toxicity ...
1. 5-year survival was significantly greater in the liver transplantation plus chemotherapy group compared to chemotherapy alone. 2. Serious adverse ...
1. Overall survival was significantly greater in the fruquintinib group versus placebo. 2. The majority of adverse events were mild-to-moderate ...
Overall tumour response to monotherapy treatment with adagrasib was 23% 46% in combination with cetuximab. Median progression-free survival was 5.6 ...
1. The median progression-free survival was marginally increased in the atezolizumab group. 2. Adverse events of grades 3 and 4 ...
